Management & Ownership
The Company was founded by academic scientists in 2011, and has received seed funding from Medical Innovation Partners and PBG FMC to conduct pre-clinical validation and set up non-GMP manufacturing.
Péter GÁL DSC
CTO
Principal Scientist at EvolVeritas Group Leader at Enzymology RCNS
Pál Gábor PHD
CEO, CTO
Co-CEO and Scientific Director at EvolVeritas
Associate Professor at Eötvös Loránd University
gellért cseh md
Business development manager
Head of Business Dev. at EvolVeritas Healthcare economist, Investment & Project Manager
zoltán uzonyi md
CEO
Co-CEO at EvolVeritas
Healthcare economist, Investment Manager, Company creation
About The Company
EvolVeritas Ltd. is a spinoff biotech company founded by scientists studying the molecular mechanism of complement activation through structure-driven protein engineering, directed protein evolution and enzymology. The mission of the company is to pickup and further develop practical results of academic discoveries, which opens new avenues for the treatment of serious diseases with high unmet medical need.
EvolVeritas is properly equipped and well positioned to become a significant player in generating research tool ligands for discovering new drug targets and for developing drug candidate compounds.
The company has received seed funding from professional investors.
Team & Platform
Dr. Gábor Pál and Dr. Péter Gál: Lead scientists, renowned for their breakthrough studies on the biological roles of complement activating proteinases. Their pioneering scientific achievements were enabled by the technology platform ‘directed protein evolution by phage display’, which was mastered by Dr. Gábor Pál at Genentech (a US based leading biotech company). He introduced the technology in his laboratory at the Department of Biochemistry of Eötvös Loránd University ten years ago, and more recently at EvolVeritas Ltd.
The phage display platform allows production, efficacy-based selection, and optimization of extremely large numbers of peptides and proteins. The initial population is usually based on naturally occurring proteins/peptides. Several billion variants are generated by rational design-guided combinatorial mutagenesis. This peptide/protein library is selected for binding to a target protein (e.g. a receptor or an enzyme) to yield potent enzyme inhibitors or receptor agonists/antagonists in a short time. This is a tremendously efficient platform to generate new peptides or proteins that can be used as research tools for breakthrough discoveries as well as novel drug candidate compounds that meet unmet therapeutic challenges.
Area of activity and disease targets
Researchers at the Eötvös Loránd University (ELTE) and the Institute of Enzymology in the Research Centre for Natural Sciences of the Hungarian Academy of Sciences (MTA) have been developing several generations of complement protease inhibitors. One of their lead compounds is under development for the treatment of various complement related diseases. The company owns IP rights for the lead compounds.
Potential indications include: (1) ischemia-reperfusion injuries (e.g. myocardial infarction, stroke; renal- or intestinal-or peripheral arterial thrombosis); rare complement mediated diseases, such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), other thrombotic microangiopathies, e.g. thrombotic thrombocytopenic purpura (TPP) and age related macular degeneration (AMD).